Premium
Management of patients with chronic rhinosinusitis during the COVID‐19 pandemic—An EAACI position paper
Author(s) -
Klimek Ludger,
Jutel Marek,
Bousquet Jean,
Agache Ioana,
Akdis Cezmi A.,
Hox Valerie,
Gevaert Philippe,
Tomazic Peter Valentin,
Rondon Carmen,
Cingi Cemal,
ToppilaSalmi Sanna,
Karavelia Aspasia,
Bozkurt Banu,
FörsterRuhrmann Ulrike,
Becker Sven,
Chaker Adam M.,
Wollenberg Barbara,
Mösges Ralph,
Huppertz Tilman,
Hagemann Jan,
Bachert Claus,
Fokkens Wytske
Publication year - 2021
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.14629
Subject(s) - medicine , covid-19 , chronic rhinosinusitis , pandemic , medline , intensive care medicine , sinusitis , cochrane library , position paper , disease , dermatology , surgery , pathology , meta analysis , infectious disease (medical specialty) , political science , law
Background Chronic rhinosinusitis is regarded as a chronic airway disease. According to WHO recommendations, it may be a risk factor for COVID‐19 patients. In most CRSwNP cases, the inflammatory changes affecting the nasal and paranasal mucous membranes are type‐2 (T2) inflammation endotypes. Methods The current knowledge on COVID‐19 and on treatment options for CRS was analyzed by a literature search in Medline, Pubmed, international guidelines, the Cochrane Library and the Internet. Results Based on international literature, on current recommendations by WHO and other international organizations as well as on previous experience, a panel of experts from EAACI and ARIA provided recommendations for the treatment of CRS during the COVID‐19 pandemic. Conclusion Intranasal corticosteroids remain the standard treatment for CRS in patients with SARS‐CoV‐2 infection. Surgical treatments should be reduced to a minimum and surgery preserved for patients with local complications and for those with no other treatment options. Systemic corticosteroids should be avoided. Treatment with biologics can be continued with careful monitoring in noninfected patients and should be temporarily interrupted during the course of the COVID‐19 infection.